ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC) Fails To Meet Endpoint On Important Trails


Dallas, Texas 02/25/2014 (FINANCIALSTRENDS) – ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC) is a US based company which brings clinical-stage Biotechnology Company which works on the immune-based therapies. These therapies are aimed at treating various cancers – brain, ovary as well as solid tumors.

ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) has been working on its lead product ICT-107 for some time now. The company has however found that the Phase 2 trials for it has failed to meet the primary endpoint itself. The country is now in quick talks with FDA on the future scope of trails in Phase 3.

The product is expected to be in the same league as the DVAX-L , a NorthWest product which is expected to see a whole range of investors.

ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) has for a long timenow been engaged in developing cancer biology techniques to cure cancer. This has meant that the vaccines this company develops are found to have higher efficacy over traditional vaccines currently available for treating cancer.

ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) is known to engage in dendrite cells technology which will build the antigen processing as well as presentation of the immune system. This helps in stimulating the immune response of the cancer cells. This will further prevent the occurrence of tumor in the patient.

ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) currently has a pipeline which include ICT-107 a lead candidate in Phase 2, developed to fight GBM or glioblastomamultiforme. The advantage with what IMUC is able to offer is that it can fight more than six types of possible antigens. These are handled with dendritic cells.

ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) also offers ICT-140 dendritic cell vaccine which are in the Phase 1 level. These are developed to fight ovarian cancer cells. The other product which is currently carries high expectation is the ICT-121. This is a phase 1 candidate and will develop recurrent form of GBM. The vaccine is expected to target CD 133, which is known to be stem cell maker.